Clinical trials: Neuroepithelial Tumor
Adult Brain Tumor, Adult Giant Cell Glioblastoma
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking…
- Conditions
- Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00379080
- Testing
- conventional surgery, tandutinib, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Cereset for Caregivers
In this single arm, open label study, investigators will evaluate the feasibility of using the Cereset (formerly known as HIRREM - high-resolution relational, resonance-based electroencephalic mirroring) intervention for a…
- Trial name
- CERESET (NCT03935269)
- Testing
- Cereset Research Wearable, Stress management therapy, Questionnaire administration
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Phase 2 Study of IDH305 in Low Grade Gliomas
Cohort A - neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the…
- Trial name
- NCT02987010
- Testing
- IDH305
- Sponsor
- University of Texas Southwestern Medical Center
Sarcoma
Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014313
- Testing
- cisplatin, etoposide
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment.
- Conditions
- CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Childhood Ependymoma
- Trial name
- NCT03387020
- Testing
- Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00887146
- Testing
- concomitant temozolomide (TMZ), radiotherapy, procarbazine
- Where
- 291 sites in United States, Austria and 4 more
- Volunteers
- 305 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain Cancer
Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
The goal of this clinical research study is to compare IMRT with IMPT in patients with glioblastoma. Researchers want to learn about cognitive side effects (mental status changes) that may occur, such as memory loss and impaired…
- Trial name
- NCT01854554
- Testing
- IMPT, IMRT, Cognitive Tests
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma
Radiosurgery and Avastin for Recurrent Malignant Gliomas
The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).
- Trial name
- NCT01017250
- Testing
- Stereotactic Radiosurgery (SRS), Bevacizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Neuroblastoma
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002560
- Testing
- monoclonal antibody 3F8, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2…
- Trial name
- BRAIN (NCT00345163)
- Testing
- bevacizumab, irinotecan
- Volunteers
- 167 people
- Sponsor
- Genentech, Inc.
Brain Tumors, Medulloblastoma
Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline
Radiation constitutes an integral component in the management of primary brain tumors in pediatric and young adults like medulloblastoma, ependymoma, low-grade glioma, pituitary tumors, etc.
- Conditions
- Brain Tumors, Medulloblastoma, Glioma, Ependymoma
- Trial name
- BIO-RIN (NCT06779487)
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Tata Memorial Centre
Glioblastoma
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted…
- Trial name
- PRIDE (NCT05871021)
- Testing
- Dose escalation of radiation dose beyond the therapeutic standard
- Where
- 9 sites in Germany
- Volunteers
- 107 people
- Sponsor
- University Hospital Tuebingen
Low Grade Glioma (LGG), High Grade Glioma (HGG)
Confocal Laser Endomicroscopy for Brain Tumors
Confocal Laser Endomicroscopy (CLE) could be a useful tool for real-time diagnosis of brain lesions (initial diagnosis or follow-up post resection to check for residual dysplasia) and real-time assessment of resections margins…
- Trial name
- GLIOFOCAL (NCT02240758)
- Testing
- confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
High Grade Gliomas, Hypoxia Brain
Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response
High-grade gliomas (HGGs) are the most common type of brain cancer in adults. Life expectancy for patients with HGGs is low. Radiotherapy aims to cure the tumour, but this is hard because HGGs are resistant to treatment.
- Conditions
- High Grade Gliomas, Hypoxia Brain, Glioblastoma (GBM), Brain Neoplasms, Adult
- Trial name
- BRIGHTER (NCT07670455)
- Testing
- Oxygen-Enhanced MRI (OE-MRI)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Gliomas, Medulloblastoma
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
The main purpose of this study is to determine the safety of using the combination of decitabine and a cancer vaccine plus Hiltonol.
- Conditions
- Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
- Trial name
- NCT02332889
- Testing
- Vaccine (autologous dendritic cells), Decitabine and Hiltonol
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Louisville
Healthy Volunteers, Recurrent Glioma
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission…
- Conditions
- Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT05676489
- Testing
- [F-18]MeFAMP PET
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Neuroblastoma (NBL), Ewing Sarcoma
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
This study will test a chimeric antigen receptor (CAR) T-cell treatment combined with bevacizumab in children and young adults with relapsed or refractory neuroblastoma, Ewing sarcoma, or osteosarcoma.
- Conditions
- Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma
- Trial name
- GD2CART-BEV (NCT07897968)
- Testing
- Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Glioma
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents
- Trial name
- NCT00147160
- Testing
- Temozolomide, Cisplatinum
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 87 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Glioma
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.
- Trial name
- IMAGLIO (NCT07120984)
- Testing
- L19TNF, L19TNF and TMZ, L19TNF and CCNU
- Volunteers
- 52 people
- Sponsor
- Philogen S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.